CUPERTINO, Calif., Sept. 26, 2019 /PRNewswire/ -- DURECT Corporation
(Nasdaq: DRRX) announced today that James
E. Brown, Chief Executive Officer will be presenting at the
Cantor Fitzgerald Global Health Care Conference, at the
InterContinental New York Barclay Hotel on Friday, October 4, 2019 at 10:40 a.m. EDT. Institutional investors and
analysts that are attending the conference may request a one-on-one
meeting through the conference coordinators.
A live audio webcast of the presentation will be available by
accessing http://wsw.com/webcast/cantor10/drrx/
The live audio webcast of the presentation will also be
available by accessing DURECT's homepage at www.durect.com and
clicking on the "Investors" tab. If you are unable to
participate during the live webcast, the call will be archived on
DURECT's website in the "Event Calendar" of the "Investors"
section.
About DURECT Corporation
DURECT is a biopharmaceutical company actively developing
therapeutics based on its Epigenetic Regulator Program and
proprietary drug delivery platforms. DUR‑928, a new chemical
entity in Phase 2 development, is the lead candidate in DURECT's
Epigenetic Regulator Program. An endogenous, orally
bioavailable small molecule, DUR-928 has been shown in preclinical
studies to play an important regulatory role in lipid homeostasis,
inflammation, and cell survival. Human applications may
include acute organ injury such as alcoholic Hepatitis (AH) and
acute kidney injury (AKI), chronic hepatic diseases such as
nonalcoholic steatohepatitis (NASH), and inflammatory skin
conditions such as psoriasis and atopic dermatitis. DURECT's
advanced oral and injectable delivery technologies are designed to
enable new indications and enhanced attributes for small-molecule
and biologic drugs. Key product candidates in this category
include POSIMIR® (bupivacaine extended-release
solution), an investigational locally-acting, non-opioid analgesic
intended to provide up to 3 days of continuous pain relief after
surgery, a long-acting injectable SABER-based HIV investigational
product being developed with Gilead, and ORADUR™-Methylphenidate ER
Capsules, approved in Taiwan as
Methydur Sustained Release Capsules, where it is indicated for the
treatment of attention deficit hyperactivity disorder (ADHD).
In addition, for the assignment of certain patent rights, DURECT
receives single digit sales-based earn-out payments from U.S. net
sales of Indivior's PERSERIS™ (risperidone) drug for
schizophrenia, which was commercially launched in February
2019. For more information about DURECT, please visit
www.durect.com.
DURECT Forward-Looking Statement
The statements in this press release regarding the potential
uses and benefits of DUR-928, POSIMIR, an HIV investigational
product being developed with Gilead, ORADUR Methylphenidate ER
Capsules, and DURECT's oral and injectable delivery technologies,
as well as potential revenues from commercial sales of Indivior's
PERSERIS, are forward-looking statements involving risks and
uncertainties that can cause actual results to differ materially
from those in such forward-looking statements. Potential risks and
uncertainties include, but are not limited to, the risks that
potential adverse effects may arise from the testing or use of
DUR-928, that Gilead may not continue to develop the
investigational HIV product, that POSIMIR may not be approved by
the FDA, that ORADUR-Methylphenidate ER may not be commercially
successful in territories where it is approved or approved in other
territories, that Indivior will not generate significant sales of
PERSERIS, that DURECT may not avoid infringing patents held by
other parties or be unable to secure and defend its own patents,
and DURECT'S ability to manage and obtain capital to fund
operations and expenses. Further information regarding these and
other risks is included in DURECT's Form 10-Q filed on August 2, 2019 under the heading "Risk
Factors."
NOTE: POSIMIR®, SABER® and
ORADUR™, are trademarks of DURECT Corporation. Other
referenced trademarks belong to their respective owners. DUR-928,
POSIMIR and ORADUR-Methylphenidate ER Capsules are drug candidates
under development and have not been approved for commercialization
by the U.S. Food and Drug Administration or other health
authorities. Full prescribing information for PERSERIS, including
BOXED WARNING, and Medication Guide can be found at
www.perseris.com.
View original
content:http://www.prnewswire.com/news-releases/durect-to-present-at-the-2019-cantor-fitzgerald-global-health-care-conference-300925808.html
SOURCE DURECT Corporation